Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D

Verastem, Inc.

Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).
As of Nov 26, 2025: doublet in G12C-naive patients achieved ORR 40% (12/30), mPFS 11.1 months.
Previously G12C-treated patients in doublet: ORR 9.5% (2/21), mPFS 3.7 months.
Triplet combo: ORR 50% (2/4) in naive; 36% (4/11) tumor reduction in pretreated.
VS-7375 showed 69% ORR (11/16) in KRAS G12D NSCLC; no DLTs observed across RAMP 203.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.